An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...

Medically reviewed by Jay N. Yepuri, MD Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ...

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and ...

Rare Disease Day is February 28. Primary sclerosing cholangitis or PSC is a rare liver disease characterized by progressive ...

Primary sclerosing cholangitis (PSC) is a chronic autoimmune disease with inflammation and stricture formation in the bile ducts inside the liver and/or in the extrahepatic bile duct which drains into ...

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

Acute cholangitis is a serious infection of the bile duct system, often caused by a blockage due to gallstones or other factors. It can lead to severe complications if not treated promptly.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

These quiz questions about primary biliary cholangitis (PBC) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician ...

Dr. Yeh will oversee the continued clinical development of NGM Bio’s key programs, NGM120 for hyperemesis gravidarum and cancer cachexia, and ...

We read with great interest the study by Wunsch et al 1 published in this issue of Polish Archives of Internal Medicine, which validated the prognostic ability of 2 previously ide ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...